Thomas Berg
#118,564
Most Influential Person Now
Researcher
Thomas Berg's AcademicInfluence.com Rankings
Thomas Bergcomputer-science Degrees
Computer Science
#4699
World Rank
#4961
Historical Rank
Machine Learning
#1010
World Rank
#1025
Historical Rank
Artificial Intelligence
#1233
World Rank
#1255
Historical Rank
Database
#1904
World Rank
#1998
Historical Rank
Download Badge
Computer Science
Thomas Berg's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Thomas Berg Influential?
(Suggest an Edit or Addition)Thomas Berg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017) (2984)
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (2009) (1941)
- Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) (1285)
- Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. (2010) (1216)
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (2018) (1034)
- ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
- Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis (2001) (860)
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015) (764)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. (2006) (564)
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014) (477)
- Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. (2007) (450)
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C (2005) (425)
- Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection (2004) (405)
- Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper (2020) (395)
- Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis (2008) (378)
- A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis (2015) (376)
- Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues (2010) (346)
- Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. (2004) (333)
- Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease (2011) (316)
- Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy (2002) (311)
- Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy (2006) (303)
- Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) (295)
- High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial (2010) (294)
- Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians (2010) (291)
- Update of the statements on biology and clinical impact of occult hepatitis b virus infection. (2019) (285)
- Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation (1998) (280)
- Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up (2004) (272)
- Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. (2009) (258)
- Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study (2006) (253)
- Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. (2014) (252)
- Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. (2014) (249)
- Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection (2005) (248)
- Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. (2011) (239)
- Expert opinion on the treatment of patients with chronic hepatitis C (2009) (232)
- A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis (2006) (229)
- Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. (2005) (222)
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. (2017) (218)
- Strategies to manage hepatitis C virus (HCV) disease burden (2014) (218)
- Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. (2010) (215)
- The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B (2017) (214)
- Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
- Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors (2015) (201)
- Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. (2010) (197)
- Increasing applicability of liver transplantation for patients with hepatitis B–related liver disease (2002) (197)
- Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
- Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. (2017) (193)
- Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians (2014) (187)
- [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
- IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study (2011) (184)
- Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. (2005) (183)
- [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. (2011) (181)
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. (2016) (179)
- First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. (2008) (176)
- Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis (2012) (174)
- Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. (2012) (168)
- Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response (2011) (167)
- Omega‐3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines (2007) (163)
- Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B (2015) (159)
- Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences (2004) (158)
- Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. (2008) (157)
- Hepatitis C treatment in “difficult‐to‐treat” psychiatric patients with pegylated interferon‐alpha and ribavirin: Response and psychiatric side effects (2007) (152)
- The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. (2013) (150)
- Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. (2010) (147)
- Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. (2009) (147)
- The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120). (2020) (146)
- Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease (2015) (144)
- Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores (2020) (133)
- Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
- Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system (2010) (124)
- Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. (2011) (123)
- Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
- GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. (2019) (120)
- Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions (1996) (120)
- Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy (2014) (119)
- Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. (2017) (119)
- Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic (2020) (116)
- The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis (2011) (113)
- Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. (2012) (112)
- Computational methods for the design of effective therapies against drug resistant HIV strains (2005) (111)
- Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. (2019) (111)
- Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. (2010) (111)
- Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). (2016) (110)
- Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease (2011) (105)
- The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. (2008) (104)
- Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. (2011) (102)
- MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (101)
- A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. (2007) (101)
- Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. (2007) (99)
- PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. (2020) (98)
- Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. (2013) (96)
- Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin (2006) (94)
- Evaluation of liver disease progression in the German hepatitis C virus (1b)‐contaminated anti‐D cohort at 35 years after infection (2014) (93)
- Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis (2018) (93)
- Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients (2013) (91)
- Tenofovir treatment in patients with lamivudine‐resistant hepatitis B mutants strongly affects viral replication (2002) (90)
- Detection of sequences of TT virus, a novel DNA virus, in German patients. (1998) (89)
- Randomized, double‐blind, placebo‐controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C (2000) (88)
- Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. (2010) (88)
- aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. (2020) (87)
- Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort (2011) (86)
- Combined effects of different interleukin‐28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection (2012) (86)
- Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients (2016) (86)
- Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection (2006) (84)
- IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis (2017) (83)
- A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. (2009) (82)
- Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes (2016) (82)
- Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. (2015) (82)
- Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol‐related cirrhosis (2018) (79)
- Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. (2000) (79)
- Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. (2014) (78)
- Induction of Interleukin-6 by Hepatitis C Virus Core Protein in Hepatitis C–Associated Mixed Cryoglobulinemia and B-Cell Non–Hodgkin's Lymphoma (2006) (78)
- Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. (1999) (77)
- Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second‐line Therapy for Patients With Autoimmune Hepatitis (2017) (76)
- Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. (2018) (75)
- Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. (2010) (75)
- MMF and Calcineurin Taper in Recurrent Hepatitis C After Liver Transplantation: Impact on Histological Course (2005) (74)
- The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C (2012) (73)
- Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis (2011) (73)
- Association of TLR7 single nucleotide polymorphisms with chronic HCV‐infection and response to interferon‐a‐based therapy (2007) (72)
- Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. (2001) (72)
- Relationship between the interleukin‐28b gene polymorphism and the histological severity of hepatitis C virus–induced graft inflammation and the response to antiviral therapy after liver transplantation (2011) (72)
- Mutations in the E2‐PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment (2000) (71)
- Isoforms of Retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver (2008) (71)
- ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. (2017) (70)
- Triple therapy with amantadine in treatment‐naive patients with chronic hepatitis C: A placebo‐controlled trial (2003) (70)
- Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial (2011) (69)
- The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells. (2009) (68)
- FibroGENE: A gene-based model for staging liver fibrosis. (2016) (68)
- The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. (2008) (68)
- [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. (2007) (68)
- The membrane‐bound O‐acyltransferase domain‐containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B (2017) (68)
- Pregnancy in primary sclerosing cholangitis (2011) (67)
- Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. (2004) (67)
- Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease (2012) (66)
- Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response (2011) (66)
- Differential priming of CD8 and CD4 T‐cells in animal models of autoimmune hepatitis and cholangitis (2007) (66)
- Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumours (2012) (65)
- Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers (2020) (65)
- High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients (2012) (65)
- Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. (2013) (65)
- Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin (2009) (65)
- Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. (1997) (65)
- Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers (2017) (65)
- Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. (1997) (64)
- Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment (2018) (64)
- [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
- Responsiveness to interferon alpha treatment in patients with chronic hepatitis C coinfected with hepatitis G virus. (1996) (63)
- Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) (2017) (63)
- Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. (2020) (63)
- A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. (2019) (63)
- A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C (2012) (62)
- Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development (2013) (62)
- Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients (2009) (61)
- Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry (2019) (61)
- Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma (2007) (60)
- Potentially inappropriate liver transplantation in the era of the "sickest first" policy - A search for the upper limits. (2017) (58)
- [Extrahepatic manifestations of chronic hepatitis C virus infection]. (2009) (58)
- Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany. (1996) (58)
- Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients (2015) (57)
- Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis (2009) (57)
- Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. (2017) (57)
- Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. (2020) (57)
- A clinical and virological study of hepatitis C virus-related cryoglobulinemia in Germany. (1998) (54)
- Loss of hepatic Mboat7 leads to liver fibrosis (2020) (54)
- Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B (2018) (54)
- Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. (2003) (53)
- MBOAT 7 rs 641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016) (53)
- Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. (2014) (52)
- Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis. (2021) (52)
- GB virus C infection in patients with chronic hepatitis B and C before and after liver transplantation. (1996) (50)
- rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis (2020) (50)
- Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). (2007) (50)
- Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. (2017) (50)
- Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease (2007) (49)
- Intrahepatic cholestasis in common chronic liver diseases (2013) (48)
- Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. (2014) (48)
- Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging (2019) (48)
- Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. (2007) (48)
- Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. (1998) (47)
- Autoimmune Hepatitis—Immunologically Triggered Liver Pathogenesis—Diagnostic and Therapeutic Strategies (2019) (47)
- Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry (2017) (47)
- Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. (2011) (47)
- Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients (2007) (46)
- The Marburg I variant (G534E) of the factor VII–activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet‐derived growth factor BB (2009) (46)
- Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. (2011) (46)
- 58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY (2008) (45)
- Chances and limitations of non‐invasive tests in the assessment of liver fibrosis in liver transplant patients (2010) (45)
- Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier. (2013) (45)
- Non-Invasive Evaluation of Cystic Fibrosis Related Liver Disease in Adults with ARFI, Transient Elastography and Different Fibrosis Scores (2012) (44)
- The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. (2014) (44)
- Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis (2017) (44)
- Management of chronic hepatitis B: status and challenges beyond treatment guidelines. (2010) (43)
- Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. (2008) (43)
- Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. (2017) (42)
- Dynamics of GB Virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication (1999) (42)
- P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program (2015) (42)
- [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. (2018) (42)
- Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. (2009) (41)
- New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C (2013) (41)
- Antiviral Therapy of Chronic Hepatitis B (2014) (41)
- HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance Interpretation Algorithm Integrating Bioinformatic Knowledge (2012) (40)
- Real‐world use, effectiveness and safety of anti‐viral treatment in chronic hepatitis C genotype 3 infection (2017) (40)
- Recurrence of autoimmune hepatitis after liver transplantation. (1999) (40)
- Effects of the CCR5-Δ32 mutation on antiviral treatment in chronic hepatitis C (2003) (40)
- 49 PEGINTRON MAINTENANCE THERAPY IN CIRRHOTIC (METAVIR F4) HCV PATIENTS, WHO FAILED TO RESPOND TO INTERFERON/RIBAVIRN (IR) THERAPY: FINAL RESULTS OF THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL (2009) (39)
- Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection (2012) (39)
- CC chemokine receptor 5 Δ32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia (2003) (39)
- Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (2004) (39)
- The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. (2009) (39)
- Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C (2003) (38)
- Haplotype‐tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C (2004) (38)
- 43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA (2013) (38)
- Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. (2004) (38)
- Occurrence and clinical outcome of lamivudine‐resistant hepatitis B infection after liver transplantation (2001) (38)
- Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. (2002) (38)
- PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). (2020) (37)
- Placebo‐controlled trial of 400 mg amantadine combined with peginterferon alfa‐2a and ribavirin for 48 weeks in chronic hepatitis C virus‐1 infection (2008) (36)
- Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. (2015) (36)
- Hepatitis C virus (HCV)-infection and oral lichen planus. (1998) (36)
- Increased Level of Interleukin 6 Associates With Increased 90‐Day and 1‐Year Mortality in Patients With End‐Stage Liver Disease (2017) (36)
- Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus (2015) (35)
- The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. (2012) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes. (1996) (34)
- Impact of the MELD allocation after its implementation in liver transplantation (2011) (34)
- Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). (2021) (34)
- Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. (2011) (34)
- The German guideline for the management of hepatitis B virus infection: short version * (2008) (34)
- Occurrence of a novel DNA virus (TTV) infection in patients with liver diseases and its frequency in blood donors (1999) (34)
- Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. (1998) (34)
- S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ (2018) (34)
- Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. (2007) (33)
- Acoustic radiation force impulse (ARFI) elastography in acute liver failure: necrosis mimics cirrhosis. (2011) (33)
- Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C (2011) (33)
- Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. (2020) (33)
- 2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL (2012) (32)
- Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. (2012) (32)
- Impaired Insulin Sensitivity as an Underlying Mechanism Linking Hepatitis C and Posttransplant Diabetes Mellitus in Kidney Recipients (2009) (32)
- Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1 (2003) (32)
- DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection (2015) (32)
- A systematic review and meta‐analysis of HCV clearance (2017) (32)
- GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. (2005) (32)
- A cross-linguistic comparison of slips of the tongue (1987) (32)
- A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti‐hepatitis B virus surface antigen immunoprophylaxis (1997) (31)
- T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study (2012) (31)
- Influence of donor/recipient HLA‐matching on outcome and recurrence of hepatitis C after liver transplantation (2006) (31)
- Randomized, placebo‐controlled, double‐blind trial with interferon‐α with and without amantadine sulphate in primary interferon‐α nonresponders with chronic hepatitis C (2001) (31)
- Comparative sequence analysis of the core‐ and NS5‐region of hepatitis C virus from tumor and adjacent non‐tumor tissue (2001) (31)
- Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic Hepatitis B: Week 72 TDF data and week 24 Adefovir dipivoxil switch data (Study 102) (2008) (31)
- 988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM (2008) (30)
- Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon (2010) (30)
- Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. (2019) (29)
- Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. (2008) (29)
- Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B (2018) (29)
- Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. (2020) (29)
- Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation. (1998) (28)
- Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B (2018) (28)
- Long‐term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation (1999) (28)
- Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores (2012) (28)
- The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection (2011) (28)
- Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. (2017) (28)
- The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C (2011) (27)
- Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis (2021) (27)
- 76 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN SUBJECTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (ADV) (2008) (26)
- Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C (2014) (26)
- Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B. (2020) (26)
- Antagonism of the chemokine Ccl 5 ameliorates experimental liver fibrosis in mice (2010) (26)
- Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. (2022) (26)
- High‐dose silibinin rescue treatment for HCV‐infected patients showing suboptimal virologic response to standard combination therapy (2012) (26)
- Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection (2016) (26)
- Apolipoprotein E allele frequencies in chronic and self‐limited hepatitis C suggest a protective effect of APOE4 in the course of hepatitis C virus infection (2016) (26)
- Epidemiological and Clinical Aspects of Hepatitis G Virus Infection in Blood Donors and Immunocompromised Recipients of HGV-Contaminated Blood (1998) (26)
- Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population (2018) (25)
- Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-&agr;-2a and ribavirin (2010) (25)
- [S3 guideline hepatitis C addendum]. (2015) (25)
- Loss of paraspinal muscle mass is a gender‐specific consequence of cirrhosis that predicts complications and death (2018) (25)
- Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion (2020) (25)
- The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. (2011) (25)
- Hepatology - A Clinical Textbook, Fifth Edition (2014) (25)
- Effects of stepped psychooncological care on referral to psychosocial services and emotional well‐being in cancer patients: A cluster‐randomized phase III trial (2017) (25)
- Prevention of Hepatitis B Recurrence after Liver Transplantation (2005) (25)
- ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials (2014) (24)
- Noninvasive characterization of graft steatosis after liver transplantation (2015) (24)
- 11 OPERA-1 TRIAL: INTERIM ANALYSIS OF SAFETY AND ANTIVIRAL ACTIVITY OF TMC435 IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS (2009) (24)
- IL 28 B , HLA-C , and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort : A Cross-Sectional Study (2011) (24)
- Interleukin 18 Promoter Variants (−137G>C and −607C>A) in Patients with Chronic Hepatitis C: Association with Treatment Response (2009) (24)
- Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome (2020) (24)
- DISTINCT ENZYME PROFILES IN PATIENTS WITH CRYPTOGENIC CIRRHOSIS REFLECT HETEROGENEOUS CAUSES WITH DIFFERENT OUTCOMES AFTER LIVER TRANSPLANTATION (OLT): A LONG-TERM DOCUMENTATION BEFORE AND AFTER OLT (2002) (23)
- Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis (2017) (23)
- The tandem‐repeat polymorphism of the DC‐SIGNR gene in HCV infection (2006) (23)
- The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy. (2021) (23)
- Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis (2018) (23)
- A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance (2015) (22)
- The Etiology, Diagnosis and Prevention of Liver Cirrhosis (2013) (22)
- Transjugular intrahepatic portosystemic shunt: Experiences at a liver transplantation center (2000) (22)
- Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials (2017) (22)
- Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting (2018) (22)
- Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. (2000) (22)
- A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. (2014) (22)
- Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation (2000) (22)
- Hepatitis B virus wild‐type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir‐based regimen (2013) (21)
- Epidemiological and Clinical Aspects of Hepatitis G Virus Infection in Blood Donors and Immunocompromised Recipients of HGV‐Contaminated Blood (1998) (21)
- FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program. (2011) (21)
- T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. (2022) (21)
- Reactivation of viral replication after replacement of tenofovir by adefovir (2005) (21)
- Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. (2001) (21)
- Retreatment with Interferon-Alpha and Ribavirin in Primary Interferon-Alpha Non-Responders with Chronic Hepatitis C (2000) (21)
- 73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE (2008) (21)
- Quantitative detection and typing of hepatitis D virus in human serum by real-time polymerase chain reaction and melting curve analysis. (2010) (21)
- TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients (2012) (21)
- An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. (2021) (20)
- Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs (2020) (20)
- 4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR (2010) (20)
- Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B (2020) (20)
- Survival after liver transplantation for hepatocellular carcinoma in cirrhosis according to the underlying liver disease. (2001) (20)
- A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment (2020) (20)
- N‐acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury (2018) (20)
- Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1 HMR Spectroscopy (2014) (20)
- Influence of the CXCL1 rs4074 A Allele on Alcohol Induced Cirrhosis and HCC in Patients of European Descent (2013) (20)
- Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α (2007) (20)
- Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma (2020) (19)
- Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis (2014) (19)
- Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C. (2015) (19)
- Outcome after liver re‐transplantation in patients with recurrent chronic hepatitis C (2007) (19)
- Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry (2018) (19)
- Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper (2022) (19)
- Percutaneous Transjugular Direct Porto-caval Shunt in Patients with Budd-Chiari Syndrome (2006) (18)
- Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. (2002) (18)
- The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. (2012) (18)
- Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation (1996) (17)
- A Common Variant of PNPLA3 (p.I148M) Is Not Associated with Alcoholic Chronic Pancreatitis (2012) (17)
- Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS) (2021) (17)
- Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. (2003) (17)
- Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy (2012) (17)
- PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C (2014) (17)
- Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection (2014) (17)
- Real‐world experience with daclatasvir plus sofosbuvir ± ribavirin for post‐liver transplant HCV recurrence and severe liver disease (2017) (17)
- Persistent hepatitis G virus infection after neonatal transfusion. (1998) (17)
- Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients (2014) (17)
- Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin (2007) (17)
- [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. (2019) (17)
- A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B (2018) (17)
- 903 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (2009) (17)
- Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (2020) (16)
- Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. (2003) (16)
- 1058 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY (2009) (16)
- European Ravs Database: Frequency and Characteristics of Ravs in Treatment-Naïve and DAA-Experienced Patients (2016) (16)
- Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. (2000) (16)
- Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-&agr; and ribavirin: results from a randomized, placebo-controlled, double-blind trial (2007) (16)
- A frequent keratin 8 p.L227L polymorphism, but no point mutations in keratin 8 and 18 genes, in patients with various liver disorders (2004) (16)
- SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients (2014) (16)
- Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality. (2019) (16)
- Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 (2008) (16)
- COVID‐19 and the liver – Lessons learned (2021) (16)
- HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. (2010) (15)
- 1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY – A RANDOMIZED CONTROLLED TRIAL (2009) (15)
- Application of Qualitative and Quantitative Real-Time PCR, Direct Sequencing, and Terminal Restriction Fragment Length Polymorphism Analysis for Detection and Identification of Polymicrobial 16S rRNA Genes in Ascites (2014) (15)
- Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma (2018) (15)
- Influence of Donor Histology on Outcome in Patients Undergoing Transplantation for Hepatitis C (2007) (15)
- Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure (2018) (15)
- Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. (1999) (15)
- CD154, a marker of antigen‐specific stimulation of CD4 T cells, is associated with response to treatment in patients with chronic HCV infection (2011) (15)
- [Acute liver failure following the use of ecstasy (MDMA)]. (2002) (15)
- Tailored treatment for hepatitis C. (2008) (15)
- Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. (2018) (15)
- Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. (2012) (14)
- Searching for the optimal management of hepatitis C patients after liver transplantation (1998) (14)
- Prevention of lamivudine‐resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only (2011) (14)
- Evaluation of the transforming growth factor beta1 codon 25 (Arg-->Pro) polymorphism in alcoholic liver disease. (2008) (14)
- Keratin 8 Y54H and G62C mutations are not associated with liver disease (2004) (14)
- The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care (2020) (13)
- O119 : Stopping tenofovir disoproxil fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial (“finite CHB”) (2015) (13)
- No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. (2008) (13)
- Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. (2020) (13)
- Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis (2021) (13)
- A case of HBV-induced liver failure in the REEF-2 Phase 2 trial: Implications for finite treatment strategies in HBV 'cure'. (2022) (13)
- The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. (2007) (13)
- Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination (2020) (13)
- Safety and Antiviral Activity of Tmc435350 in Treatment-name Genotype 1 Hcv-infected Patients (2008) (13)
- Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease (2008) (13)
- Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis (2018) (13)
- Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. (2008) (13)
- New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy (2014) (13)
- Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study (2017) (13)
- 328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1 (2003) (13)
- Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment (2006) (13)
- Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B (2013) (13)
- [613] VIROLOGICAL RESPONSE AT 4 AND 12 WEEKS PREDICT HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN (2007) (13)
- Fatal Outcome of Hepatitis A Virus (HAV) Infection in a Traveler with Incomplete HAV Vaccination and Evidence of Rift Valley Fever Virus Infection (2008) (12)
- The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? (2011) (12)
- Stopping Tenofovir Disoproxil Fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial („FINITE CHB“) (2015) (12)
- Induction of T helper cell type 1 response and elimination of HBeAg during treatment with IL-12 in a patient with therapy-refractory chronic hepatitis B. (2001) (12)
- Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss (2020) (12)
- Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients – epidemiologic and molecular evidence (2006) (12)
- Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2019) (12)
- The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis (2014) (12)
- Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection. (2003) (12)
- Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. (2009) (11)
- INTERSEGMENTAL COHESIVENESS (1989) (11)
- Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alfa-2a and ribavirin (2010) (11)
- A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease (2014) (11)
- Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. (2001) (11)
- Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV‐infected renal allograft recipients (2004) (11)
- Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B (2021) (11)
- Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment (2018) (11)
- Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection (2022) (11)
- Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders (2016) (11)
- 943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial (2012) (11)
- Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. (1998) (11)
- Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection (2013) (11)
- Genetic Contribution to Alcohol Dependence: Investigation of a Heterogeneous German Sample of Individuals with Alcohol Dependence, Chronic Alcoholic Pancreatitis, and Alcohol-Related Cirrhosis (2017) (10)
- Cholesterol esterification in plasma as a biomarker for liver function and prediction of mortality (2017) (10)
- Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation (2018) (10)
- Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C. (2019) (10)
- Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti‐HCV therapy? (2016) (10)
- Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation (2000) (10)
- Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection (2020) (10)
- Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial (2002) (10)
- Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival (2016) (10)
- Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis? (2009) (10)
- The effects of multi-disciplinary psycho-social care on socio-economic problems in cancer patients: a cluster-randomized trial (2018) (10)
- Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease (2017) (9)
- A survey of chronic hepatitis B patient management practices in the European Union (2010) (9)
- TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (2000) (9)
- Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. (2013) (9)
- Ascites’ neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation (2016) (9)
- Treatment Outcomes for Hepatitis C Genotype 1 Infection with Direct Acting Antivirals: Data from the German Hepatitis C-Registry (2016) (9)
- Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. (2002) (9)
- First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry (2018) (9)
- 54 COMPLETELY INDIVIDUALIZED TREATMENT DURATIONS (24, 30, 36, 42, 48, 60 OR 72 WEEKS) WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS (INDIV-2 STUDY) (2010) (9)
- Flares during long‐term entecavir therapy in chronic hepatitis B (2016) (9)
- Combined effects of different IL 28 B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection (2011) (9)
- Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha (2001) (9)
- Interferon- l rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease (2015) (9)
- Mononuclear-cell-derived microparticles attenuate endothelial inflammation by transfer of miR-142-3p in a CD39 dependent manner (2018) (9)
- Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial (2021) (9)
- Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection (2013) (9)
- Association of HLA‐DPA1 and HLA‐DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians (2019) (9)
- ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B : RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (9)
- 74 THE ANTIVIRAL RESPONSE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IS COMPARABLE IN LAMIVUDINE (LAM)-NAIVE AND LAM-EXPERIENCED SUBJECTS TREATED FOR CHRONIC HEPATITIS B (CHB) (2008) (9)
- The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure (2021) (9)
- [Expert recommendations: Hepatitis C and transplantation]. (2016) (8)
- Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study (2012) (8)
- Treatment of HBV related cirrhosis (2013) (8)
- Reply to: Correspondence on 'the times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.' (2021) (8)
- Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany (2021) (8)
- Elevated concentrations of 15‐deoxy‐Δ12,14‐prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor γ‐inducing drugs (2009) (8)
- The antiviral response to Tenofovir disoproxil fumarate (TDF) is comparable in Lamivudine (LAM)-naïve and LAM-experienced subjects treated for chronic Hepatitis B (CHB) (2008) (8)
- 739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES (2011) (8)
- 923 SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS (2009) (8)
- Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion. (2022) (8)
- [German guidelines on diagnosis and therapy of hepatitis B]. (2007) (8)
- Isatoribine, a toll-like receptor 7 agonist, significantly reduced plasma viral load in a clinical proof-of-concept study in patients with chronic hepatitis C virus infection. (2004) (8)
- Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study (2022) (8)
- Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies (2014) (8)
- Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease (2021) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- Randomized, controlled trial with interferon-alpha (IFN-alpha) combined with ribavirin with and without amantadine sulfate in primary IFN-alpha nonresponsive patients with chronic hepatitis C (2001) (8)
- Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial (2014) (8)
- Age dependence of liver enzymes: an analysis of over 1,300,000 consecutive blood samples. (2021) (8)
- Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus (2021) (8)
- A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. (2011) (8)
- Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges (2019) (8)
- Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers (2021) (7)
- TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. (2017) (7)
- Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2). (2019) (7)
- Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B. (2021) (7)
- HBsAg and anti-HCV screening in elderly hospitalized patients of a German tertiary referral centre (2016) (7)
- The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu (2019) (7)
- Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort (2010) (7)
- [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases]. (2000) (7)
- Absolute quantification of microparticles by flow cytometry in ascites of patients with decompensated cirrhosis: a cohort study (2017) (7)
- Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program (2016) (7)
- 431 HETEROZYGOUS ALPHA-1 ANTITRYPSIN DEFICIENCY AS AN INHERITED RISK FACTOR IN THE DEVELOPMENT OF CHRONIC LIVER DISEASE (2009) (7)
- APC mosaicism in a young woman with desmoid type fibromatosis and familial adenomatous polyposis (2018) (7)
- Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry (2021) (7)
- Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C (2013) (7)
- FRI-199-First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis (2019) (7)
- Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe (2015) (7)
- Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany (2022) (7)
- Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity (2015) (7)
- Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites (2019) (7)
- Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure. (2016) (7)
- Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements (2003) (7)
- Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation – A Simple Intervention Ensures High Adherence (2019) (7)
- Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients (2018) (7)
- All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study (2014) (7)
- Kinetics of hepatitis C viremia after orthotopic liver transplantation. (1997) (6)
- The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021) (6)
- PS-177-HSD17B13 rs72613567 TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis (2019) (6)
- Interim Results of a Double-blind, Randomized Phase 2 Study of the Safety of Tenofovir Disoproxil Fumarate, Emtricitabine plus Tenofovir Disoproxil Fumarate ,and Entecavir in the treatment of chronic hepatitis B subjects with Decompensated liver disease (2009) (6)
- Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adefovir dipivoxi (2008) (6)
- M1923 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) (2008) (6)
- Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - Data from the German Hepatitis C-Registry (DHC-R) (2020) (6)
- N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART. (2007) (6)
- Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial (2014) (6)
- 768 Treatment of recurrent hepatitis C after liver transplantation with peginterferon alfa-2B and ribavirin (2003) (6)
- [Current recommendations for the treatment of chronic hepatitis C]. (2014) (6)
- Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples (2020) (6)
- Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease (2017) (6)
- 381 A Multicenter Analysis of Antiviral Response After One Year of Tenofovir Mono-Therapy in HBV-Monoinfected Patients with Prior Nucleos(t)ide Analog Experience (2008) (6)
- Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. (1998) (6)
- 792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY (2013) (6)
- 295 Final Results of the EPIC3 Cirrhosis Maintenance Trial: Pegintron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients, Who Failed to Respond to Interferon/Ribavirn (IR) Therapy: (2009) (6)
- [Prognostic relevance of hepatitis C virus genotype for responsiveness to interferon-alpha]. (1995) (6)
- Resistance remains a problem in treatment failure (2014) (6)
- Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study (2015) (6)
- 48 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED CONTROLLED GERMAN HEP-NET ACUTE HCV-III STUDY (2012) (6)
- Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection (2019) (6)
- A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (6)
- Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD) (2020) (5)
- Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program (2016) (5)
- A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C (2014) (5)
- Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). (2019) (5)
- rs641738C>T near MBOAT7 promotes steatosis, NASH, fibrosis and hepatocellular carcinoma in non-alcoholic fatty liver disease: a meta-analysis (2020) (5)
- Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting (2018) (5)
- Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey (2022) (5)
- Antiviral combination therapy for lamivudine‐resistant hepatitis B reinfection after liver transplantation (2000) (5)
- Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. (2022) (5)
- [Long-term follow-up of chronic hepatitis C after treatment with recombinant interferon alpha-2a]. (1994) (5)
- CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection (2013) (5)
- No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. (2013) (5)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study (2010) (5)
- 559 Individualized treatment strategy with peginterferon alpha-2b (PEG-IFN a) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients (2006) (5)
- 929 EVALUATION OF SAFETY AND TOLERABILITY OF TENOFOVIR DF (TDF) LONG TERM MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE EXPERIENCED PATIENTS WITH HBV MONOINFECTION (2009) (5)
- Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials (2018) (5)
- [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response]. (2000) (5)
- P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis (2015) (5)
- Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. (2016) (5)
- Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. (1997) (5)
- Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection (2015) (5)
- Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study (2020) (5)
- A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis (2021) (5)
- 793 REAL-LIFE DATA OF TELAPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GT1 IN GERMANY – AN INTERIM ANALYSIS (2013) (4)
- The Practicability of the Xpert HCV Viral Load Fingerstick Point-of-Care Assay in Primary Care Settings (2021) (4)
- Liver transplantation in hepatitis B patients with preoperative resistance formation during lamivudine treatment. (2002) (4)
- Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? (2019) (4)
- P1314 : Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT STUDY) (2015) (4)
- More on Intersegmental Cohesiveness (1994) (4)
- 333 Citalopram for prevention of interferon-alpha associated depression in psychiatric risk patients (2003) (4)
- Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver (2020) (4)
- Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy (2010) (4)
- LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) (2021) (4)
- Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany (2019) (4)
- Role of tenofovir in the treatment of chronic HBV infection (2008) (4)
- Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin (2009) (4)
- 544 A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES (2012) (4)
- Reply to: "underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients". (2014) (4)
- Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) (2017) (4)
- Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing (2019) (4)
- [Procedures for problematic situations with hepatitis B]. (2004) (4)
- Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in hereditary haemochromatosis (2021) (4)
- Determination of HIV-1 co-receptor usage in German patients – comparison of genotypic methods with the TROFILE® phenotypic assay (2008) (4)
- 1028 RENAL SAFETY AND ANTIVIRAL EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE REFRACTORY PATIENTS WITH HEPATITIS B VIRUS (HBV) MONO-INFECTION (2010) (4)
- Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study (2015) (4)
- Evaluation of muscarinic acetylcholine receptor type 3 gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis (2019) (4)
- Safety and efficacy of direct oral anticoagulants under long‐term immunosuppressive therapy after liver, kidney and pancreas transplantation (2020) (4)
- Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection. (2011) (4)
- Acute hepatitis C virus infection induces anti‐host cell receptor antibodies with virus‐neutralizing properties (2015) (4)
- Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis (2022) (4)
- Evaluation of angiotensinogen c.1-44G>A and p.M268T variants as risk factors for fibrosis progression in chronic hepatitis C and liver diseases of various etiologies. (2009) (4)
- Telaprevir‐based triple‐therapy in patients with chronic hepatitis C in Germany: a 12‐week interim analysis of real‐life data (2012) (4)
- Long-term follow-up in hepatitis C patients with respect to immunosuppression. (1996) (4)
- Therapie der rekurrenten Hepatitis-B-Infektion nach Lebertransplantation (2000) (4)
- P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study (2015) (4)
- Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression (2013) (4)
- 296 Importance of ribavirin dosage on virological response rates in patients chronically infected with hepatitis C virus and treated with interferon-based combination therapy (2003) (4)
- Hepcidin as a predictor of treatment response in chronic hepatitis C infection (2014) (4)
- 770 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBsAg LOSS IN HBeAg NEGATIVE CHB PATIENTS: FOLLOW-UP OF LONG TERM RESPONDERS (2013) (4)
- Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest (2022) (3)
- Recurrent hepatitis C infection after orthotopic liver transplantation. (1995) (3)
- Sex-dependent dynamics of metabolism in primary mouse hepatocytes (2021) (3)
- From the Editor's desk...: July 2016. (2016) (3)
- OWE-016 Genetic variants in PNPLA3 and TM6SF2 predispose to hepatocellular carcinoma in patients with alcohol-related cirrhosis (2018) (3)
- Re-evaluation of the genetic cirrhosis risk score in patients with chronic hepatitis C virus infection (2009) (3)
- FRI-212-HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos (t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B (2019) (3)
- Serological diagnosis of early HCC in NASH: A German multicenter study (2018) (3)
- 1017 EFFICACY OF TENOFOVIR DF TREATMENT IN PATIENTS WITH A SUBOPTIMAL RESPONSE TO ADEFOVIR DIPIVOXIL (2010) (3)
- O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
- Safety and Efficacy of IFN- Free Antiviral Therapies in Advanced HCV- Associated Liver Cirrhosis: Results from the German Hepatitis C-Registry (DHC-R) (2016) (3)
- Genetic Variants in the Promoter Region of the Macrophage Migration Inhibitory Factor are Associated with the Severity of Hepatitis C Virus-Induced Liver Fibrosis (2019) (3)
- 1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis (2015) (3)
- Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome (2017) (3)
- Incidence and clinical relevance of recurrent hepatitis C infection after orthotopic liver transplantation (1994) (3)
- 1020 SAFETY AND EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN INTERNATIONAL MULTICENTER COHORT STUDY (2010) (3)
- Multicenter, randomized, double-blind, placebo-controlled trial of interferon-a (IFN-a2a) with and without amantadine as treatment for IFN-A non-responders with chronic hepatitis C (2000) (3)
- Rral-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C GT1 in Germany – an interim analysis (2013) (3)
- 36 SILIBININ AS A RESCUE TREATMENT FOR HCV-INFECTED PATIENTS SHOWING SUBOPTIMAL VIROLOGIC RESPONSE TO STANDARD COMBINATION THERAPY (2010) (3)
- Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha. (2001) (3)
- [Hepatitis G virus infection: the epidemiological aspects and clinical relevance]. (1997) (3)
- 394 MUTATIONS IN THE HBS-ANTIGEN INFLUENCE THE RESULTS OF HBSAG QUANTIFICATION ASSAYS (2011) (3)
- Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis (2022) (3)
- DNA methylation in breast and colorectal cancer'. (2008) (3)
- Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial (2021) (3)
- 642 INDIVIDUALIZED TREATMENT DURATION WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN FOR 24, 30 OR 36 WEEKS IN HCV GENOTYPE1-INFECTED PATIENTS WITH UNDETECTABLE HCV-RNA EARLY DURING THERAPY (INDIV-2 STUDY) (2009) (3)
- Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study (2018) (3)
- Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. (2020) (3)
- rs641738C>T near MBOAT7 is positively associated with liver fat, ALT, and histological severity of NAFLD: a meta-analysis (2019) (3)
- Long‐Term Colestyramine Treatment Prevents Cholestatic Attacks in Refractory Benign Recurrent Intrahepatic Cholestasis Type 1 Disease (2020) (3)
- 928 EFFECTIVENESS OF TENOFOVIR DF (TDF) MONOTHERAPY IN PATIENTS WITH PRIOR EXPERIENCE TO NUCLEOSIDE/NUCLEOTIDE ANALOGUES BY DIFFERENT PATTERN OF PRE-EXISTING MUTATIONS (2009) (3)
- P1272 IDENTIFICATION OF HBV AND HCV INFECTIONS IN THE PRIMARY CARE SETTING: PRE-DEFINED RISK SCENARIOS ARE A BETTER SCREENING STRATEGY THAN ELEVATED ALT VALUES (2013) (3)
- GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates (1999) (2)
- P0643 : Serum HBV RNA is an early predictor of HBeAg seroconversion in patients with chronic hepatitis B (CHB) treated with Peg-Interferon alpha-2A (40kD) (2015) (2)
- Long-term efficacy of interferon alpha treatment in chronic hepatitis C. (1998) (2)
- Stopping long-term NUCs therapy before HBsAg loss in HBeAg negative patients: follow-up of long-term responders (2013) (2)
- 1050 TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY (2009) (2)
- Hepatitis B recurrence in relation to immunosuppression and acute allograft rejection. (1996) (2)
- From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice (2021) (2)
- [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis]. (2008) (2)
- Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease (2022) (2)
- 831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3 (2009) (2)
- Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. (2013) (2)
- [521] MULTIFACTORIAL ANALYSIS OF HOST AND VIRUS RELATED RISK FACTORS FOR THE DEVELOPMENT OF VIRAL RESISTANCE DURING LONG-TERM LAMIVUDINE TREATMENT OF HBV INFECTION OVER UP TO NINE YEARS (2007) (2)
- Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease (2020) (2)
- S1000 Results from the Epic3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the RE-Treatment of Previous Interferon/Ribavirin Non-Responders (Nr) (2008) (2)
- Genetic variation of PNPLA3 and TM6SF2 associate with hepatocellular carcinoma in patients with alcohol-related cirrhosis (2017) (2)
- Randomized, controlled trial with interferon-α (IFN-α) combined with ribavirin with and without amantadinsulfat in primary IFN-α non-responders with chronic hepatitis C (2001) (2)
- 322 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil (2009) (2)
- Farnesoid-X Receptor single nucleotide polymorphism rs35724 is potentially associated with patients’ outcome in decompensated liver cirrhosis (2017) (2)
- Challenges of LC-MS/MS ethyl glucuronide analysis in abstinence monitoring of liver transplant candidates (2020) (2)
- Increased mortality after liver transplantation for hepatocellular carcinoma in hepatitis B-associated cirrhosis (2003) (2)
- Dual proteotoxic stress accelerates liver injury via activation of p62‐Nrf2 (2021) (2)
- From the Editor's desk....: January 2016. (2016) (2)
- 1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV (2011) (2)
- 301 Chronic hepatitis-C infection, interferon-alpha treatment and peripheral serotonergic dysfunction (2003) (2)
- Five-Year-Experience with High-MELD Recipients (≥30 Points) - Single-Centre Results and Re-Evaluation of Prognostic Models for Postoperative Survival: 1872 (2012) (2)
- Liver transplantation in HBsAg+ patients with postoperative immunoprophylaxis. (1997) (2)
- P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES (2014) (2)
- Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study (2017) (2)
- Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience (2022) (2)
- Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study) (2009) (2)
- Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial (2009) (2)
- Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (>70 Yrs): Results from the German Hepatitis C-Registry (2016) (2)
- Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection (2013) (2)
- PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure (2019) (2)
- 455 HCV VIRAL KINETICS DURING RIBAVIRIN MONOTHERAPY: RESULTS OF A RANDOMIZED PARTIALLY DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL (2011) (2)
- Efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in a European multicenter cohort of nucleos(t)ide experienced patients with chronic hepatitis B virus (HBV)-infection (2010) (2)
- [Diagnosis and clinical features of infection with hepatitis A and hepatitis E viruses. Transmission through drinking water and foodstuffs]. (2011) (2)
- Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis (2019) (2)
- Hepatitis C virus - A teacher of clinical research, cell biology and immunology. (2016) (2)
- Tapered steroid treatment leads to distinct ALT response patterns in patients with acute severe hepatitis, and may help to distinguish AIH from DILI (2017) (2)
- 820 Keratin 8 Y53H and G61C mutations are no genetic risk factors for developing cryptogenic or noncryptogenic liver disease (2003) (2)
- 822 PLATELET COUNT PREDICTS SUSTAINED VIRAL RESPONSE (SVR) IN THE RE-TREATMENT OF PREVIOUS INTERFERON/RIBAVIRIN NON-RESPONDERS (NR): RESULTS FROM THE EPIC3 PROGRAM (2008) (2)
- [Minimal effects of acute liver failure on hemostasis]. (2013) (2)
- Impact of immunosuppression and acute rejection on hepatitis B recurrence. (1997) (2)
- Copeptin – a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease (2019) (2)
- A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes (2022) (2)
- Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry (2022) (2)
- Hepatocellular Carcinoma Prevention by Aspirin: Are Platelets the Link? (2021) (2)
- Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B (2021) (2)
- 415 HIGH PREVALENCE OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN A GERMAN METROPOLITAN AREA: A PROSPECTIVE SCREENING ANALYSING 7683 PATIENTS (2009) (2)
- Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study (2021) (2)
- Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections (2019) (2)
- Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients (2018) (2)
- Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
- Inconsistencies in pro ANT-OAR position. (2006) (1)
- Morphological slips of the tongue (2020) (1)
- Adressen (2018) (1)
- TREATMENT OF HCV-RE-INFECTION AFTER LIVER TRANSPLANTATION WITH SILIBININ IN NON-RESPONDERS TO A PEGYLATED INTERFERON BASED THERAPY: 1939 (2010) (1)
- Long-term evaluation of patients with sustained virologic remission by highly sensitive HCV RNA assays: no evidence for viral persistence. (2011) (1)
- 512 Serotonergic dysfunction during chronic hepatitis C infection among patients with drug addiction compared to controls (2004) (1)
- Elevated concentrations of 15-deoxy-Δ12,14-Prostaglandin J2 in chronic liver disease propose therapeutic trials with PPARgamma inducing drugs (2009) (1)
- Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type (2016) (1)
- 1351 PREDICTION OF RELAPSE AFTER PEGINTERFERON ALFA-2B/RIBAVIRIN THERAPY IN CHRONIC HCV GENOTYPE 1 PATIENTS IS DEPENDENT ON MINIMAL RESIDUAL VIREMIA BUT NOT ON IL28B GENOTYPE (2011) (1)
- 123 Pegylated interferon alpha-2a treatment in HCV positive patients after liver transplantation (2006) (1)
- [Current status of treatment for chronic viral hepatitis using recombinant interferon alpha]. (1994) (1)
- 232 TRAIL RECEPTOR I POLYMORPHISMS C626G AND A638C ARE ASSOCIATED WITH AN INCREASED RISK FOR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN HCV-INFECTED PATIENTS (2011) (1)
- Add on Interferon-Alpha-2a for the treatment of hbeag negative Hepatitis B patients receiving effective nucleos (t)ide therapy: interim results of the prospective multicentre padd-on trial (2016) (1)
- 744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (1)
- P0644 : HCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) (2015) (1)
- Gene therapy for Wilson disease : (2015) (1)
- 837 ASSOCIATION BETWEEN AN INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 2 (IRAK2) VARIANT AND SPONTANEOUS VIRAL CLEARANCE OF HCV (2012) (1)
- Mo1411 - An Integrated Analysis of the Efficacy of Glecaparevir/Pibrentasvir by Geographical Region (2018) (1)
- Schémas and lexical blends (1)
- Treatment of Patients with Hepatitis C Virus (HCV) Genotype 3 Infection in the Era of Direct Acting Antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R) (2016) (1)
- Correlation between mutations in the E2 region of HCV genotype 1 isolates and responsiveness to IFNα (2000) (1)
- From the Editor's desk…From the Editor's desk: September 2016. (2016) (1)
- Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study (2005) (1)
- Three are better than one-increasing HBV seroprotection by a tri-antigenic vaccine. (2021) (1)
- 709 LONG-TERM TREATMENT WITH LAMIVUDINE UP TO TEN YEARS: PREDICTIVE VALUE OF HOST AND VIRUS RELATED RISK FACTORS FOR THE DEVELOPMENT OF HBV RESISTANCE (2008) (1)
- From the editor's desk ... (2015) (1)
- O10 Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure; results of the first multicenter randomized trial (GRAFT study) (2021) (1)
- 2014 IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC3 PROGRAM (2010) (1)
- Risk factors for the acquisition of hepatitis C. (2005) (1)
- No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) when Given Alone or in Combination with Emtricitabine (FTC) in Chronic Hepatitis B (CHB) Patients with Documented Resistance to Lamivudine (LAM): Final 5 Year Results (2015) (1)
- 409 The DC-signR tandem-repeat polymorphism in hepatitis C virus infection (2004) (1)
- 312 Evaluation of angiotensinogen -6G>A and M235T single nucleotide polymorphisms as inherited risk factors for the progression of chronic liver disease of different etiologies (2004) (1)
- 290 EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR (2010) (1)
- Tenofovir effectively inhibits viral replication in different patient groups with lamivudine resistant HBV infection (2003) (1)
- Identification of the chemokine CXCL9 (MIG) as a genetic modifier of liver fibrosis in patients with hepatitis C (2006) (1)
- 1357 A LARGE-SCALE GENETIC VALIDATION STUDY COUPLED WITH IN-VITRO ANALYSES REVEAL A ROLE OF VITAMIN D-SIGNALING IN THE PATHOGENESIS AND TREATMENT OF CHRONIC HEPATITIS C (2011) (1)
- Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting (2018) (1)
- [Acute and acute-on chronic-liver failure]. (2013) (1)
- Silibinin in hepatitis C related liver transplantation (2011) (1)
- Acute-on-Chronic Liver Failure (2018) (1)
- Lamivudine as first‐ and second‐line treatment of hepatitis B infection after liver transplantation (2000) (1)
- 188 Interacting gene variants modify the response to combination therapy with interferon-alpha and ribavirin in patients with chronic hepatitis C (2003) (1)
- Interferon-alpha treatment and serotonergic dysfunction (2004) (1)
- Letter: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients – authors’ reply (2016) (1)
- Invasive Cardiac Aspergillosis after Orthotopic Liver Transplantation (2014) (1)
- [Liver transplantation - current trends]. (2020) (1)
- 1304 TH2 CYTOKINE-MEDIATED BILIARY EPITHELIAL CELL (BEC) BARRIER DYSFUNCTION MAY CONTRIBUTE TO IMMUNOGLOBULIN G4 (IGG4) ASSOCIATED SCLEROSING CHOLANGITIS (IAC) (2011) (1)
- Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotype 1 infection and elevated GGT levels (2012) (1)
- Toll-like receptor 4 inhibition acts synergistically with G-CSF to prevent organ injury and induce liver regeneration in acute-on-chronic liver failure (2020) (1)
- From the Editor’s desk...: January 2018 (2018) (1)
- P805 NON-INVASIVE CHARACTERIZATION OF POST-TRANSPLANT FATTY LIVER DISEASE REVEALS HIGH PREVALENCE OF GRAFT INJURY IN ASSOCIATION WITH METABOLIC SYNDROME, RECIPIENT PNPLA3 GENOTYPE AND ALCOHOLIC LIVER CIRRHOSIS (2014) (1)
- Influence of immunosuppression on patient outcome after liver transplantation. (1998) (1)
- Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. (2016) (1)
- Combination of amantadine with interferon alpha and ribavirin in patients with chronic hepatitis C leads to a reduction of T-helper cell type 2 reactivity (2003) (1)
- Long-term follow-up of hepatitis C virus infected recipients after orthotopic liver transplantation (1993) (1)
- Occurence and clinical outcome of lamivudine resistant hepatitis B reinfection after liver transplantation (2001) (1)
- 558 Evaluation of alpha-1-antitrypsin allele frequencies as an inherited risk factor for the development of chronic liver disease of different etiologies (2004) (1)
- 1092 EFFECTS OF PRE-TREATMENT WITH BEZAFIBRATE FOLLOWED BY STANDARD OF CARE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION AND ELEVATED GGT LEVELS (2012) (1)
- New perspectives in the treatment of HBeAg‐positive and HBeAg‐negative chronic hepatitis B (2005) (1)
- Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients". (2018) (1)
- Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs – Results from the German Hepatitis C-Registry (DHC-R) (2019) (1)
- Identification of patients with HBV and HCV infection in the primary care setting: Pre-defined risk scenarios are a better screening strategy than elevated ALT values (2013) (1)
- Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals (2022) (1)
- From the Editor's desk...: June 2018. (2018) (1)
- SAT-277-Screening diabetic patients at risk for complications of nonalcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations (2019) (1)
- Toll-like receptor 5 polymorphism at position c. 1846T > C is associated with the development of hepatocellular carcinoma in caucasians with chronic hepatitis B infection (2017) (1)
- Transient Howell-Jolly-body-like cytoplasmic inclusions in neutrophils after severe intoxication with alpha-lipoic acid (2020) (1)
- 379 Long-Term Treatment with Lamivudine Up to Ten Years: Predictive Value of Host and Virus Related Risk Factors for the Development of HBV Resistance (2008) (1)
- 603 A SURVEY OF CHRONIC HEPATITIS B PATIENT MANAGEMENT PRACTICES IN EUROPE (2008) (1)
- 592 Evaluation of Genome-Wide Loci of Iron Metabolism in Hereditary Hemochromatosis Identifies Pcsk7 as a Predictor of Liver Cirrhosis (2012) (1)
- 1172 Multifactorial analysis of host and virus related risk factors for the development of viral resistance during long-term lamivudine treatment of HBV infection (2003) (1)
- 134 EVALUATION OF GENOME-WIDE LOCI OF IRON METABOLISM IN HEREDITARY HEMOCHROMATOSIS IDENTIFIES PCSK7 AS A PREDICTOR OF LIVER CIRRHOSIS (2012) (1)
- Intrahepatic cholestasis of pregnancy resistant to both therapeutic plasma exchange and albumin dialysis (2022) (1)
- [Complications of liver cirrhosis]. (2011) (1)
- Telaprevir in Combination with Peginterferon and Ribavirin In Genotype 1 HCV Treatment-Naïve Patients, Prior Relapsers and Prior Non-Responders: Pooled Analysis Of PROVE1, PROVE2, PROVE3 and Study 107: 274 (2010) (1)
- Carriage of HSD17B13 rs72613567TA is associated with a reduced risk for developing hepatocellular carcinoma in patients with alcohol-related cirrhosis (2019) (1)
- P1312 : Alfapump system versus transjugular intrahepatic portosystemic shunt and paracentesis in the treatment of ascites. A multicentre randomised controlled study (AGUA-trial) (2015) (1)
- 1053 Evaluation of alpha-1-antitrypsin allele frequencies as an inherited risk factor for the development of chronic liver disease of different etiologies (2003) (1)
- Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. (2022) (1)
- Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib (2022) (1)
- Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease (2022) (1)
- Characterization of serologic responses following ALT flares in >3000 CHB patients pooled from 5 clinical trials (2020) (1)
- Yttrium‐90 radioembolization‐induced abscopal effect on hepatocellular carcinoma (2022) (1)
- Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump (2022) (1)
- Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation (2021) (1)
- Confirmation of guideline‐defined hepatitis C screening strategies within the ‘Check‐Up35+’ examination in the primary care setting (2023) (1)
- Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression. (2021) (1)
- Common ABCB4 and ABCB11 Genotypes Are Associated with Idiopathic Chronic Cholestasis in Adults (2021) (1)
- Translation Reprogramming as a Novel Therapeutic Target in MAFLD (2022) (1)
- Variants in PCSK7, PNPLA3 and TM6SF2 are risk factors for the development of cirrhosis in people with hereditary haemochromatosis (2020) (1)
- High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis (2023) (1)
- TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients (2012) (1)
- A TWO-STAGE GENOME-WIDE ASSOCIATION STUDY IDENTIFIES TM6SF2 AND MBOAT7 AS RISK LOCI FOR ALCOHOL-RELATED CIRRHOSIS (2015) (1)
- From the Editor's desk…: May 2019. (2019) (0)
- HBsAg loss during treatment with nucleo(s)tide analogues is preceded by changes of the composition of the hepatitis B virus surface antigen (HBsAg) (2017) (0)
- A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial (2008) (0)
- Clinical characterization and long-term documentation of cryptogenic cirrhosis before and after liver transplantation (2001) (0)
- Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R) (2022) (0)
- [Position paper on the management of acute liver failure]. (2013) (0)
- Cover Image (2021) (0)
- 618 Prediction for treatment outcome in HCV type 1-infected patients: GAMMA-glutamyltranspepdidase (GGT) is the most reliable independent single parameter (2006) (0)
- Interleukin-12 (IL-12) therapy in patients with chronic hepatitis C (1998) (0)
- Reply: CORRESPONDENCE HEPATOLOGY, Month 2015 (2016) (0)
- Hohe Variabilität des NS3 1406 CD8 Epitopes mit Entwicklung von Escape Mutationen in der Frühphase der akuten Hepatitis C Virus Infektion (2007) (0)
- From the Editor’s desk…: May 2015 (2015) (0)
- From the Editor's desk....: April 2017. (2017) (0)
- From the Editor's desk...: September 2017. (2017) (0)
- From the Editor's Desk: September 2019. (2019) (0)
- Loss of the middle hepatitis B virus (HBV) surface antigen (MHBs) during interferon-alpha (PEG-IFN) treatment is associated with subsequent lower HBV replication in patients with chronic HBeAg negative hepatitis B (2019) (0)
- IL-28B Genotype is not associated with early HCV-RNA negativity in patients with symptomatic acute HCV infection (2013) (0)
- From the Editor’s desk...: September 2015 (2015) (0)
- From the Editor's desk...: August 2017. (2017) (0)
- Increased mortality after liver transplantation for hepatocellular carcinoma in hepatitis B‐associated cirrhosis (2003) (0)
- [462] ASSOCIATION OF TLR7 POLYMORPHISMS WITH RESPONSE TO INTERFERON-ALPHA-BASED THERAPY IN PATIENTS WITH CHRONIC HCV INFECTION (2007) (0)
- From the Editor's desk....: May 2018. (2018) (0)
- FRI-375-Direct oral anticoagulants are safe and effective in patients after liver/kidney transplantation (2019) (0)
- 109 The chemokine CXCL9 (MIG) is associated with liver fibrogenesis in mice and humans (2006) (0)
- Reply letter. (2021) (0)
- 912 APOLIPOPROTEIN E4 ALLELE PROTECTS FROM CHRONIC HCV INFECTION (2012) (0)
- From the Editor's desk...: February 2016. (2016) (0)
- FRI-361-Impact of cardiovascular complications on patients’ outcome after orthotopic liver transplantation (2019) (0)
- From the Editor's Desk…: December 2019. (2019) (0)
- P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION (2014) (0)
- Impact of genetic polymorphisms in the SCARB1 gene on hepatitis C virus (2015) (0)
- High concordance in results of genotypic tropism testing from viral RNA and proviral DNA using geno2pheno[coreceptor] is not influenced by viral load - results of a multicentre comparison (2011) (0)
- The HLA-DPA1 rs3077 TT polymorphism is associated with spontaneous resolution of hepatitis B virus (HBV) infections in Caucasians (2015) (0)
- THU-205-Evaluation of HBV outcomes after treatment discontinuation from 4 phase 3 studies (2019) (0)
- Treatment of Genotype 1 HCV Treatment-Naïve Patients: final results of phase III study ADVANCE (2011) (0)
- O54 SPONTANEOUS RESOLUTION OF HEPATITIS C VIRUS INFECTION IS ASSOCIATED WITH THE PRESENCE OF ANTI-RECEPTOR ANTIBODIES IN A COHORT OF SINGLE-SOURCE OUTBREAK (2014) (0)
- Journal of Hepatology: The Home of Liver Research, 2015-2019. (2019) (0)
- O53 SERUM LEVELS OF THE ENDOGENOUS HCV ENTRY INHIBITOR OXIDIZED LDL (OXLDL) PREDICT SVR FOLLOWING INTERFERON-BASED THERAPY OF CHRONIC HEPATITIS C (2014) (0)
- From the Editor's desk....: September 2018. (2018) (0)
- Quantification of serum HBV RNA allows differentiation of disease stages of hepatitis B virus (HBV) infections (2015) (0)
- Hepatitis C-committing the world to an eradication of the infection. (2020) (0)
- Variants in TM6SF2, PNPLA3 and PCSK7 are risk factors for the development of cirrhosis in people with genetic haemochromatosis (2019) (0)
- Ursodeoxycholic acid normalizes the 15 years survival in German patients with primary biliary cirrhosis and normal serum bilirubin levels at baseline (2009) (0)
- P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
- Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) (2023) (0)
- Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study) (2016) (0)
- The fraktalkine receptor CX3CR1 is associated with progression of liver fibrosis in patients with chronic hepatitis C (2006) (0)
- Comparative analysis of inflammatory biomarkers in spontaneous bacterial peritonitis and acute-on-chronic liver failure (2015) (0)
- Dynamics of lamivudine-resistant mutants (YMDD mutations) development during long-term therapy for chronic hepatitis B (2003) (0)
- From the Editor's desk.....: February 2017. (2017) (0)
- From the Editor's desk....: April 2018. (2018) (0)
- P108: Impact of genetic polymorphisms in the SCARB1 gene on hepatitis C virus (2015) (0)
- From the Editor's desk…: April 2018. (2019) (0)
- GENETIC LIVER DISEASES Gene therapy for acute intermittent porphyria (2016) (0)
- 672 IDENTIFICATION OF POLYBACTERIAL 16S RRNA GENES FROM ASCITIC FLUIDS WITH T-RFLP ANALYSIS AND DIRECT SEQUENCING (2012) (0)
- From the Editor's desk...: March 2016. (2016) (0)
- 483 IMPORTANCE OF HCV RNA ASSAY CHARACTERISTICS AND DIFFERENCES BETWEEN ASSAYS FOR RESPONSE GUIDED THERAPY OF CHRONIC HEPATITIS C (2011) (0)
- P139 HCV-SPECIFIC IGG+ MEMORY B CELLS DIRECTED AGAINST ENVELOPE PROTEIN E2 SHOW STRONG CLONAL EXPANSION AFTER SPONTANEOUS CLEARANCE OF AN HCV INFECTION IN A SINGLE-SOURCE OUTBREAK (2014) (0)
- [Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B]. (2001) (0)
- From the Editor's desk...: August 2016. (2016) (0)
- From the Editor's desk...: May 2016. (2016) (0)
- Prediction of Six and Twelve Month Mortality by Patients with Liver Cirrhosis Using a New LiMAx Test: 1523 (2012) (0)
- From the Editor's Desk…: October 2019. (2019) (0)
- Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest (FT)/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC 3 Program (2010) (0)
- Technical Modifications in Parenchymal Transection During Laparoscopic Liver Resection Do Not Confer to an Increased Rate of Cut Surface Complications Compared to Open CUSA Based Liver Resections – A Single Center Comparative Analysis (2021) (0)
- Rajiv Jalan at Liver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Hospital, UK SELECTION OF THE MONTH Big title: Implementation of four simple interventions can reduce premature alcohol related deaths (2017) (0)
- 819 IMPROVED PHARMACODYNAMICS AND PHARMACOKINETICS AFTER INTRAVENOUS APPLICATION OF PEG-INTERFERON alfa-2a 180 μg IN CHRONIC HEPATITIS C GENOTYPE 1 NULLRESPONDERS TO PEGINTERFERON/RIBAVIRIN. THE IVAN STUDY (2013) (0)
- Outbreak of hepatitis B virus infection in an ambulatory haemodialysis clinic in Germany (2003) (0)
- Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235] (2013) (0)
- 259 ANTIVIRAL EFFICACY OF RIBAVIRIN MONOTHERAPY FOLLOWED BY STANDARD COMBINATION TREATMENT IN CHRONIC HEPATITIS C (2010) (0)
- From the Editor's desk....: March 2019. (2019) (0)
- Association of genetic variants in innate immunity genes with spontaneous viral clearance and with interferon response in chronic hepatitis C virus infection (2013) (0)
- Variants in the human PPIA gene render host cells refractory to hepatitis C virus infection by destabilization of the essential host factor cyclophilin A (2012) (0)
- Big Title: Gut-Liver interaction in PSC Small titles: Sarcopenia and fibrosis in NAFLD Trends in global HBV epidemiology Dynamics of HCV replication organelles generation ACUTE LIVER INJURY (2017) (0)
- Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection (2017) (0)
- MIGHT THE MELD SCORE GET BETTER USING A DIRECT LIVER FUNCTION TEST (LIMAX TEST)?: 3141 (2010) (0)
- 9 ASSOCIATION OF A GENETIC VARIANT OF THE TOLL-LIKE RECEPTOR 9 (TLR9) WITH SPONTANEOUS VIRAL CLEARANCE AND WITH INTERFERON RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2013) (0)
- 634 The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection (2003) (0)
- Response to entecavir treatment and evolution of HBV quasispecies in patients with failure to second line treatment with adefovir (2013) (0)
- Value of Brush Cytology in the Surveillance of Patients with Primary Sclerosing Cholangitis (2006) (0)
- The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study (2019) (0)
- From the Editor's desk...: May 2017. (2017) (0)
- Reply (2014) (0)
- Comparison of lamivudine and famciclovir for hepatitis B infection after liver transplantation (1999) (0)
- Pegylated interferon-α stimulates pituitary hormone secretion during long-term therapy (2004) (0)
- From the Editor's desk....: July 2018. (2018) (0)
- Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB) (2009) (0)
- Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate (2009) (0)
- From the Editor's desk…: August 2019. (2019) (0)
- SAT-491-Assessment of liver function by 13C methacetin breath test may help to predict liver function deterioration after selective transarterial chemoembolisation of hepatocellular carcinomas (2019) (0)
- The Human Leukocyte Antigen -DPA1 RS3077 TT Polymorphism is Associated with Spontaneous Clearance of HBS Antigen in Caucasians with Chronic Hepatitis B (2016) (0)
- From the Editor’s desk...: July 2015 (2015) (0)
- Corrigendum to "From the Editor's Desk August 2018" [J Hepatol 69 (2018) 265-268]. (2018) (0)
- [Therapy of chronic hepatitis C with pegylated interferon alfa-2a]. (2001) (0)
- [763] CRITICAL EVALUATION OF CANDIDATE GENE POLYMORPHISMS IN THE DEVELOPMENT OF ALCOHOLIC LIVER CIRRHOSIS (2007) (0)
- FRI-084-Targeting Toll-Like Receptor 4 signalling with TAK-242: A novel therapy for acute liver failure (2019) (0)
- FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients (2019) (0)
- Real-world data on treatment with bulevirtide in patients with chronic hepatitis B and D coinfection (2022) (0)
- From the Editor's desk...: April 2016. (2016) (0)
- 461 Apolipoprotein E polymorphism may protect from hepatitis C virus (HCV) infection (2004) (0)
- Acoustic Radiation Force Elastography and Transient Elastography in Autoimmune Hepatitis: Left Liver Lobe Measurement Shows Better Accuracy for Early Detection of Fibrosis (2011) (0)
- Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders (2015) (0)
- 413 FIBROTEST (FT) VALUE INDEPENDENTLY PREDICTS EARLY (EVR) AND SUSTAINED VIROLOGICAL RESPONSE (SVR) IN NON-RESPONDER PATIENTS RE-TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-2B) AND RIBAVIRIN IN EPIC3 (2009) (0)
- Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure (2022) (0)
- Influence of therapy with IFN alpha 2A and consensus-IFN (IFN alpha-con) on the T-helper cell type 1 and type 2 reactivity in patients with hepatitis C (2003) (0)
- Polyunsaturated fatty acids and eicosanoids in ascites serve as potential new biomarkers for complications in liver cirrhosis (2017) (0)
- Novel PCR-based method to detect fungal colonization of ascites, bile and duodenal fluid in patients with acute on chronic liver failure (ACLF) or after orthotope liver transplantation (OLT) (2017) (0)
- From the Editor's Desk…: November 2019. (2019) (0)
- Elevated concentrations of15-deoxy-D-prostaglandin J2 in chronic liver disease propose therapeutic trialswith peroxisomeproliferator activated receptor c-inducing drugs (2009) (0)
- A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. (2023) (0)
- Conversion from CNI Based Immunosuppression to Everolimus in High MELD Patients (> 30): 2569 (2012) (0)
- Urgent need to increase awareness and screening programs for HCV infection Reliable data about the population-based prevalence of hepatitis C virus (HCV)- (2017) (0)
- Histological course of recurrent hepatitis C after liver transplantation (2003) (0)
- From the Editor's desk...: October 2016. (2016) (0)
- Meta-analysis of ISDR mutations and interferon-alpha (IFNA) sensitivity in patients with chronic hepatitis C virus (HCV) genotype 1B infection (2003) (0)
- FibroTest™ Is an Independent Predictor of Early and Sustained Virologic Response in Nonresponder Patients With Chronic Hepatitis C: Results From the EPIC 3 Study (2009) (0)
- 893 VARIATIONS OF VITAMIN D LEVELS IN GENOTYPE 1HEPATITIS C PATIENTS UNDERGOING ANTIVIRAL THERAPY CORRELATE WITH STAGE OF FIBROSIS BUT NOT WITH TREATMENT OUTCOME (2012) (0)
- Frequency and functional analysis of variants of the immunodominant epitope NS3–1073: Relevance for vaccine design (2006) (0)
- P0499 : Functional analysis of genetic variants of toll-like receptor (TLR) 9 and inteferon regulatory factor (IRF) 7 associated with the natural course of HCV infection (2015) (0)
- Persistent long-term risk of liver related complications in HCV patients after antiviral therapy - Data from the German Hepatitis C-Registry (2021) (0)
- Do elevated liver values necessarily indicate a health problem or could poorly defined upper limits of normal be an issue? Alanine aminotransferase and gamma-glutamyltransferase depend strongly on age (2017) (0)
- Sa1062 Characterization of anti-HCV Antibody Repertoire of IgG+ Memory B Cells in Patients With Chronic Hepatitis C and Spontaneous Resolvers in a Single Source Outbreak (2013) (0)
- From the Editor's Desk…: October 2018. (2018) (0)
- Association of common polymorphism in the Interleukin 1 beta gene with Hepatitis B virus-related hepatocellular carcinoma in Caucasians (2018) (0)
- Therapy with DAAs in patients with chronic hepatitis C and advanced chronic kidney disease: Real-world experience of the German Hepatitis C Registry (2018) (0)
- 10. Die explikative Dimension (1988) (0)
- Reply: To PMID 23929603. (2014) (0)
- Association of a TLR7 variant with spontaneous clearance of hepatitis B virus infection in Caucasians (2023) (0)
- From the Editor's desk...: November 2016. (2016) (0)
- 1157 NUCLEOSIDE TRANSPORTER SLC28A2/3 AND SLC29A1/2 GENETICS: PROTECTION AGAINST ANAEMIA IN CHRONIC HEPATITIS C PATIENTS RECEIVING RIBAVIRIN (2011) (0)
- P732 PREDICTIVE VALUE OF THE INTERFERON-LAMBDA 4 GENE (IFN-L4) FOR DIRECT-/ANTIVIRAL TREATMENT IN HEPATITIS C VIRUS INFECTED PATIENTS WITH GENOTYPES 1, 2, 3, AND 4 (2014) (0)
- 694 HLA CLASS I ALLELES ASSOCIATED WITH HCV POLYMORPHISMS AND RESPONSE TO ANTIVIRAL THERAPY IN HCV GENOTYPE 1-INFECTED PATIENTS (2010) (0)
- Der Tandem-Repeat Polymorphism des DC-SIGNR Gens in der Hepatitis C Virus Infektion (2004) (0)
- 1349 VIROLOGIC RELAPSE IS HIGHLY CORRELATED WITH RESPONSE AT WEEK 4 AND 12 BUT NOT WITH IL28B GENOTYPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH PEG-INTERFERON/RIBAVIRIN (2011) (0)
- Reply: (2005) (0)
- Letter to the Editor (2008) (0)
- M1912 The Antiviral Response to Tenofovir Disoproxil Fumarate (TDF) Is Comparable in Lamivudine (LAM)-NaïVe and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB) (2008) (0)
- From the Editor's desk....: November 2018. (2018) (0)
- From the Editor's desk...: October 2017. (2017) (0)
- Hepatitis C Virus (HCV) Infection: in Special Situations (2019) (0)
- Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS study) (2018) (0)
- STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4- dependent NK cell IFN-γ production (0)
- Endogenous oxidized LDL levels predict treatment response in interferon-based therapy of chronic hepatitis C (2014) (0)
- From the Editor's desk....: August 2018. (2018) (0)
- High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis (2017) (0)
- Serum IgG4 and long term outcome in patients with primary biliary cholangitis treated with ursodeoxycholic acid (2016) (0)
- Soluble urokinase plasminogen activator receptor is a marker for severity of liver fibrosis in hepatitis C infection (2010) (0)
- Response to "Defining age related thresholds for ALT and the risk of confounders" by Daniel Q. Huang, Mindie H. Nguyen. (2021) (0)
- Significance of elevated IL8 levels in patients with chronic hepatitis C in comparison with patients with liver diseases of different origin (2003) (0)
- All-trans retinoic acid co-administered with pegylated interferon and ribavirin does not influence viral kinetics in hepatitis C infected patients with previous non-response: Results of the ATRACTION study (2012) (0)
- P637 HBsAg AND ANTI-HCV SCREENING IN SENESCENT HOSPITALIZED PATIENTS OF A GERMAN TERTIARY REFERRAL CENTRE (2014) (0)
- Kidney inflammation Kidney function Kidney fibrosis Kidney inflammation Kidney function Kidney fibrosis Common bile duct ligation (2017) (0)
- 151 Influence of donor/recipient HLA matching on outcome and recurrence of HCV after orthotopic liver transplantation (2004) (0)
- From the Editor's desk…: July 2019. (2019) (0)
- Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis (2022) (0)
- Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) (2022) (0)
- 884 CXCL1 RS4074 POLYMORPHISM INFLUENCES THE SUSCEPTIBILITY TO HEPATOCELLULAR CARCINOMA (2010) (0)
- GB VIRUS C INFECTION IN CHILDREN AFTER NEONATAL TRANSFUSION (1997) (0)
- Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts (2022) (0)
- From the Editor's Desk…: October 2018. (2018) (0)
- From the Editor's desk...: March 2017. (2017) (0)
- From the Editor's desk…: June 2019. (2019) (0)
- Real-World Data on the use of Ribavirin with Ombitasvir/Paritaprevir/R with or without Dasabuvir in HCV Genotype 1 or 4-Infected Patients from the German Hepatitis C Registry (2016) (0)
- Variants APOE (rs429358) and TM6SF2 (rs187429064) confer risk to hepatocellular carcinoma (2021) (0)
- 71 ENHANCED PATTERN RECOGNITION SIGNALING IN HUMAN CHOLANGIOCYTES CONTRIBUTES TO CHRONIC INFLAMMATION IN END-STAGE CHRONIC INFLAMMATORY LIVER DISEASE (2009) (0)
- From the Editor’s desk...: June 2015 (2015) (0)
- Arthur Stoll 1887–1971 (1971) (0)
- From the Editor's desk.…: December 2018. (2018) (0)
- Co-morbidities and risk for drug-drug-interactions in HCV GT 1 patients treated with elbasvir/grazoprevir from the German Hepatitis C Registry (DHC-R) (2018) (0)
- Association of a Common Polymorphism in the Toll-Like Receptor (TLR) 3 Gene with Spontaneous HBS Antigen Clearance (2016) (0)
- Clinical predictors of interferon-induced depression in HCV-infected patients without psychiatric risk factors (2016) (0)
- From the Editor's desk... (2017) (0)
- Neutralizing Activity of Monoclonal Antibodies Directed against the HCV Glycoprotein E2 Isolated from Patients with Spontaneously Recovery from an HCV Infection in a Single-Source Outbreak (2016) (0)
- P66 SVR with telaprevir, peginterferon alfa-2A and ribavirin in HCV patients with well-characterised prior null response, partial response, viral breakthrough or relapse after peginterferon+ ribavirin (2010) (0)
- Bacterial DNA quantification in ascites: a novel tool to define high risk patients? (2015) (0)
- 1350 HOST-SPECIFIC FACTORS INDEPENDENT OF IL28B GENOTYPE PREDICTING TREATMENT OUTCOME OF INDIVIDUALIZED THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION (2011) (0)
- Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease : A break of intestinal insulin resistance ? (2010) (0)
- Polymorphisms within the Toll-like receptor 4 (TLR4) gene are associated with HBeAg-negative status and spontaneous HBsAg seroconversion in females with chronic hepatitis B virus (HBV) infections (2016) (0)
- Real life experience with selective internal radiation therapy (SIRT) as part of multimodality treatment of advanced hepatocellular carcinoma (HCC) (2018) (0)
- HBV RNA decline without concomitant HBsAg decrease is associated with a low probability of sustained response and HBsAg loss (2020) (0)
- Early changes in HBV RNA serum levels are a predictor of HBeAg seroconversion in patients with chronic hepatitis B receiving treatment with Peg-interferon alpha-2a (40KD). (2014) (0)
- Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R) (2018) (0)
- Evaluation of a rapid on-site anti-HCV test as screening tool for hepatitis C infection (2012) (0)
- Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries. (2023) (0)
- Common polymorphisms in the TLR3 gene are stronger associated with spontaneous clearance of Hepatitis B virus infection in caucasians than variants of the HLA gene (2017) (0)
- P0561 : Differences in quantitative composition of large, middle and small hepatitis B virus (HBV) surface antigen (HBsAg) In acute and chronic HBV infection (2015) (0)
- 799 EFFECTS OF RIBAVIRIN ON NK CELL PHENOTYPE AND FUNCTION IN HEPATITIS C VIRUS INFECTION (2012) (0)
- 145 Enhanced TLR Signaling Breaks Endotoxin Tolerance in Human Biliary Epithelial Cells in END-Stage Chronic Inflammatory Liver Disease (2009) (0)
- Individually Tailored Treatment Strategies in Treatment‐naïve Chronic Hepatitis C Genotype 1 Patients (2011) (0)
- The stopping rules in hepatitis B virus therapy: can we provide any guidance? (2020) (0)
- Comprehensive analysis of NK cell phenotype and function during the initial phase of antiviral therapy: distinct roles of Ribavirin and Interferon alpha (2013) (0)
- HBeAg seroconversion during treatment with peginterferon-alfa2a (PEG-IFN) is preceded by selection of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication (2020) (0)
- Low-density lipoprotein receptor polymorphisms are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection (2008) (0)
- Ravidasvir Plus Sofosbuvir For 12 Weeks in Noncirrhotic and 24 Weeks In Cirrhotic Patients With HCV Genotypes 1 , 2 , 3 , And 6 : The STORM-C-1 Phase 2 / 3 Trial (2018) (0)
- Linkage to care of HBsAg and anti-HCV positive patients after a systematic screening approach in the German primary care setting (2017) (0)
- Book reviews (1989) (0)
- From the Editor's Desk: January 2019. (2019) (0)
- FRI-262-Genetic variants in the promotor region of the macrophage migration inhibitory factor are associated with severity of HCV-induced liver fibrosis (2019) (0)
- 575 Retreatment with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in pegylated interferon α-2b (12KD)/ribavirin non-responders with cirrhosis/advanced fibrosis: Repeat interim analysis (2006) (0)
- P0131 : Bacterial DNA quantification in ascites: A novel tool to define high risk patients? (2015) (0)
- P938 BACTERIAL DNA IN NON-LEUKOCYTIC ASCITES, IDENTIFICATION OF RISK FACTORS (2014) (0)
- THU-434-Poorly chosen upper limits of normal for alanine aminotransferase may burden the patient and health system unnecessarily (2019) (0)
- Big title: NAFLD and coronary artery disease Small title (Cirrhosis): Plectin and cholestasis When achieving SVR is futile Antiviral properties of toll-like receptor 7 agonists ACUTE LIVER INJURY Involvement of hepatocyte interleukin (IL)-1 receptor in early lipopolysaccharide (LPS)-induced liver in (2018) (0)
- A specific deletion pattern in the preS1- and preS2-domain occurs during functional cure of chronic hepatitis B (2021) (0)
- HBV messenger RNA (mRNA) is a strong predictive marker for HBeAg and HBsAg loss during antiviral treatment with nucleoside/nucleotide analogues (NUCs) in patients with chronic hepatitis B virus (HBV) infection (2012) (0)
- 298 ESCITALOPRAM FOR THE PREVENTION OF PEG-IFN-α AND RIBAVIRIN ASSOCIATED DEPRESSION IN HCV-INFECTED PATIENTS: FINAL RESULTS FROM THE CIPPAD-TRIAL (2010) (0)
- 1124 FERTILITY AND PREGNANCY IN PRIMARY SCLEROSING CHOLANGITIS (2010) (0)
- [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (0)
- Reply (2005) (0)
- T cell exhaustion dynamics are linked to clinical outcomes in Hepatocellular Carcinoma (2020) (0)
- From the Editor's desk...: December 2017. (2017) (0)
- International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
- Big Title: PNPLA3 increases risk of death in alcoholic hepatitis Small title: Carvedilol increases survival of decompensated cirrhosis patients LIVER INJURIES Thymic MAP3K14 and liver homeostasis, deciphering chemotherapy-related liver injuries (CALI) (2017) (0)
- P0591 : HBV vaccination status in patients with end stage pulmonary disease evaluated for lung transplantation (2015) (0)
- Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial (2012) (0)
- 321 Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients (2009) (0)
- [575] PREDICTION OF TREATMENT RESPONSE TO 72 WEEKS OF PEGYLATED INTERFERON ALFA-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C AFTER LIVER TRANSPLANTATION (2007) (0)
- Association of variants of interleukin 10 and 12A with the progression of hepatitis B virus infection in Caucasians (2023) (0)
- [596] GENOTYPE-SPECIFIC ASSESSMENT OF PREDICTIVE FACTORS FOR SUSTAINED VIROLOGIC RESPONSE AFTER STANDARD TREATMENT IN PATIENTS CHRONICALLY INFECTED WITH HCV (2007) (0)
- International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
- 462 Influence of interleukin 12B gene (IL 12B) polymorphism in spontaneous or treatment-induced recovery from hepatitis C (HCV) infection (2004) (0)
- Genetic Variation of SAMM50 Is Not an Independent Risk Factor for Alcoholic Hepatocellular Carcinoma in Caucasian Patients (2022) (0)
- From the Editor's desk...: March 2018. (2018) (0)
- Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B (2022) (0)
- 1364 DEEP SEQUENCING REVEALS ACCUMULATION OF VIRAL VARIANTS IN HCV GENOTYPE 1 INFECTED PATIENTS DURING RIBAVIRIN MONOTHERAPY (2011) (0)
- P6: Prevalence of HCV, HBV and HIV infections among hemophiliac (2014) (0)
- [Liver transplantation]. (1998) (0)
- Latent tuberculosis progression within a collective of human immunodeficiency virus infected patients (2019) (0)
- Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. (2023) (0)
- P1095 HBVRNA IN SERUM IS A PREDICTOR OF HBeAg SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B RECEIVING TREATMENT WITH PEG-INTERFERON ALPHA-2a (40KD) (2014) (0)
- Acknowledgment of 2009 Reviewers (2010) (0)
- Neutralizing activity of non-polyreactive monoclonal antibodies directed against the Hepatitis C virus E2 glycoprotein isolated from patients with spontaneous resolution (2017) (0)
- Reply (2016) (0)
- 637 RAPID SELECTION OF ESCAPE MUTATIONS WITHIN NS3 1406 CTL EPITOPE DURING ACUTE HEPATITIS C WITH SEQUENCE VARIABILITY DUE TO IMMUNE PRESSURE (2008) (0)
- Editorial: moving towards a robust definition of sarcopenia in cirrhosis—authors' reply (2019) (0)
- 18 Differential priming of T cells by antigens expressed in hepatocytes and cholangiocytes in animal models of autoimmune hepatitis and cholangitis (2006) (0)
- 624 DIAGNOSIS OF BACTERIAL PERITONITIS BY IDENTIFICATION OF 16S RRNA GENES VIA POLYMERASE CHAIN REACTION (PCR) (2012) (0)
- Current State and Future Possibilities in Liver Transplantation. (2021) (0)
- Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular carcinoma (2022) (0)
- SAT-033-Body fat composition determines outcomes before and after liver transplantation in cirrhosis (2019) (0)
- 311 Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment (2010) (0)
- P0581 : Prediction of HBsAg seroclearance and HBsAg seroconversion in a cohort of inactive european hepatitis B (HBV) carriers: A prospective longitudinal study (albatros study) (2015) (0)
- HBV-HCV Coinfection: Insights from a Novel Model System (2008) (0)
- The composition of HBsAg during peginterferon-alfa2a treatment can predict treatment response in HBV/HDV-coinfection (2020) (0)
- P093 Toll-like receptor 4 inhibition acts synergistically with G-CSF to prevent organ injury and induce liver regeneration in acute-on-chronic liver failure (2021) (0)
- Implementation of a national registry for patients with primary biliary cholangitis (PBC): the German PBC cohort (2020) (0)
- Chronische Hepatitis C (2002) (0)
- Inside Front Cover (2019) (0)
- Authors' reply to: G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount! (2021) (0)
- P0182 : Duodenal microbiota is not the origin for bacterial translocation in liver cirrhosis (2015) (0)
- Clinical practice guidelines for acute-on-chronic liver failure: are we ready for reaching global consensus? (2023) (0)
- Mononuclear-cell-derived microparticles attenuate endothelial inflammation by transfer of miR-142-3p in a CD39 dependent manner (2018) (0)
- British Association for the Study of the Liver Meeting (2000) (0)
- G-CSF treatment in decompensated liver disease: a double-edged sword? (2022) (0)
- ANALYSIS OF IL28B GENOTYPE FOR THE SELECTION OF PATIENTS FOR AN INDIVIDUALIZED TREATMENT DURATION IN HCV GENOTYPE 1 PATIENTS (THE INDIV-1 STUDY) (2011) (0)
- The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment (2022) (0)
- Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas (2022) (0)
- From the Editor's desk...: June 2016. (2016) (0)
- Acoustic Radiation Force Impulse (ARFI) Elastografie bei erwachsenen Patienten mit zystischer Fibrose: Limitierte diagnostische Aussagekraft (2010) (0)
- From the Editor's desk...: December 2015. (2015) (0)
- [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer]. (2022) (0)
- PCR-based methods for the detection of fungal DNA in patients with chronic liver disease (2014) (0)
- The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study (2018) (0)
- New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma (2020) (0)
- GALAD score correlates with therapy response for transarterial and systemic therapies in patients with hepatocellular carcinoma (2022) (0)
- A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort (2022) (0)
- Relevance of diabetes medication on recruitment criteria for clinical studies in patients with non-alcoholic fatty disease and type 2 diabetes mellitus (2022) (0)
- End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. (2022) (0)
- The GALAD score is associated with response to loco-regional and systemic therapies for hepatocellular carcinoma (2023) (0)
- The CRAFITY score can identify patients with hepatocellular carcinoma showing poor response to treatment with atezolizumab and bevacizumab (2023) (0)
- PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy (2020) (0)
- Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease. (2023) (0)
- [658] OPTIMAL PRE-TREATMENT HCV-RNA LEVEL FOR PREDICTION OF SVR WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN IN GENOTYPE 1 PATIENTS: GENERALISED ADDITIVE LOGISTIC REGRESSION MODEL (GAM) ANALYSIS (2007) (0)
- Toll-like receptor 3 polymorphisms rs5743305 and rs3775291 affect innate immune responses in whole blood analyses (2022) (0)
- Analysis of patient’s X-ray exposure in hepatic chemosaturation procedures: a single center experience (2022) (0)
- Response to "Age dependence of liver enzymes: celiac disease should also be considered" (CGH-D-22-00387). (2022) (0)
- Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation—Adjusting the Odds? (2022) (0)
- Bacterial DNA in non-leukocytic ascites, identification of risk factors (2014) (0)
- Sachwortregister Band 10,1994 (1994) (0)
- A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (0)
- COVID vaccination among liver transplant recipients: A EASL-ESOT/ELITA-ILTS multi society survey (2022) (0)
- From the Editor's desk.... : December 2016. (2016) (0)
- [Diagnosis of chronic hepatitis]. (1997) (0)
- Serum hepatitis B virus RNA level is associated with hepatitis B virus genotype and BCP mutations in untreated patients with HBeAg positive chronic hepatitis B (2017) (0)
- Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial (2023) (0)
- 13C-methacetine breath test for the prediction of liver damage caused by transarterial chemoembolization in patients with hepatocellular carcinoma (2020) (0)
- Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression (2022) (0)
- Real-life experience with selective internal radiation therapy (SIRT) in multimodality treatment of advanced hepatocellular carcinoma (HCC) (2018) (0)
- Hepatitis B virus basal core promotor variants become selected in serum hepatitis B virus DNA but not in hepatitis B virus RNA genome in patients responding to treatment with peginterferon-alfa 2a (PEG-IFNα) (2017) (0)
- SAT-330-Whole metabolome profiling identifies the combination of an eicosanoid, a bile acid and an androgen as a highly accurate marker of liver fibrosis in patients with non-alcoholic fatty liver disease (2019) (0)
- NON-ALCOHOLIC FATTY LIVER DISEASE ( NAFLD ) NGAL as an inflammatory mediator , preserved hemostatic status in NAFLD (2016) (0)
- Thalidomide : an old drug for a new indication ? (2016) (0)
- P747 ASSOCIATION OF A GENETIC VARIANT OF THE MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN (MAVS) WITH INTERFERON RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2014) (0)
- Automated low flow ascites (ALFA) pump effectively reduces the number of large volume paracentesis - data from a real world cohort (2020) (0)
- Interleukin 10 and Interferon Gamma levels are elevated in patients with hepatocellular carcinoma showing response to treatment with atezolizumab and bevacizumab (2022) (0)
- 2020 - A new decade of innovation for EASL. (2020) (0)
- Reply to: "Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?" (2017) (0)
- Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy? (2020) (0)
- Hepatocellular Carcinoma - an Interdisciplinary Disease Pattern (2013) (0)
- Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels (2022) (0)
- Closely monitored alpha-fetoprotein allows early detection of hepatocellular carcinoma recurrence after orthotopic liver transplantation (2022) (0)
- Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort (2022) (0)
- The LiMAx level before transarterial chemoembolization or radioembolization is a predictor for short-time survival in patients with early stage HCC (2022) (0)
- Whole metabolome profiling identifies the combination of an eicosanoid, a bile acid and an androgen as a highly accurate marker of liver fibrosis in patients with non-alcoholic fatty liver disease (2019) (0)
- From the Editor's desk...: November 2015. (2015) (0)
- Subject Index, Vol. 10, 1994 (1994) (0)
- Inhalt – Contents, Vol. 10, 1994 (1994) (0)
- Dynamics in Circulating y -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial (2022) (0)
- P0331 : The ‘GALAD score’ for serological detection of hepatocellular carcinoma: International validation and assessment of the influence of tumour size and aetiology on model utility (2015) (0)
- Ultrasonic Interference Loudspeaker (1998) (0)
- Corrigendum (2022) (0)
- The predictive value of serum Dickkopf-related protein 1 in evaluation tumor response to transarterial radioembolization in patients with hepatocellular carcinoma (2023) (0)
- A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis. (2020) (0)
- Surrogate markers for hepatitis B Virus covalently closed circular DNA. (2022) (0)
- Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population (2018) (0)
- Prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma (2020) (0)
- Genetically determined expression of lipoprotein lipase is linked to hepatocellular carcinoma in alcohol-associated cirrhosis (2023) (0)
- Reply to: 'Depiction of alcohol-related liver disease in the EASL International Liver Congress'. (2022) (0)
- Deletions in the HBV s gene are associated with altered HBsAg composition in patients with HBsAg loss during NA therapy (2021) (0)
- Contents, Vol. 43, 1986 (1986) (0)
- Heterogeneity of hepatitis B virus (HBV) basal core promotor (BCP) variants during treatment with peginterferon alfa-2a is associated with low HBV replication (2023) (0)
- The sexual dimorphism of primary murine hepatocytes changes during cultivation (2021) (0)
- Association of Toll-like receptor 4 (TLR4) gene polymorphisms with remission of chronic hepatitis B infections in female patients (2016) (0)
- Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry (2022) (0)
- Tick-tock – Circadian regulation of liver metabolism represented in a kinetic model (2023) (0)
- Autorenverzeichnis Band 10, 1994/Author Index, Vol. 10, 1994 (1994) (0)
- Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. (2021) (0)
- Eyes on the lab (2001) (0)
- Contents, Vol. 40, 1971 (1971) (0)
- Notice for authors (1976) (0)
- Reply (2021) (0)
- Gender disparity in the association of interleukin-10 and interleukin-12 polymorphisms with the progression of hepatitis B virus infection in Caucasians (2020) (0)
- Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis (2022) (0)
- [In Process Citation]. (2014) (0)
- Acoustic Radiation Force Elastography and Transient Elastography in Cystic Fibrosis: Liver Stiffness Is not increased in CF-Related Liver Disease in Adults (2011) (0)
- Granulocyte colony stimulating factor (G-CSF) to treat acute (on chronic) liver failure: effect on immune and stem cell mobilisation (2014) (0)
- Chronic HCV-infection, interferon-alpha treatment and peripheral serotonergic dysfunction (2004) (0)
- LBO‐01: First in human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis B (2018) (0)
- Pegylated interferon-α augments basal and stimulated GH and PRL secretion during long-term therapy in patients with chronic hepatitis C (2005) (0)
- 534 Complement factor 5 is no genetic risk factor for the progression of liver fibrosis in chronic hepatitis C infection (2006) (0)
- RISK FACTORS FOR GRAFT FAILURE DUE TO RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION. (2004) (0)
- P738 NO CLINICALLY RELEVANT DRUG–DRUG INTERACTIONS BETWEEN FALDAPREVIR AND PEGYLATED INTERFERON a-2a PLUS RIBAVIRIN IN HCV-INFECTED PATIENTS: PHARMACOKINETIC ANALYSES FROM TWO PHASE II STUDIES (2014) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Interleukin-12 (IL-12) treatment in chronic hepatitis C (1998) (0)
- From the Editor's desk...: May 2017. (2017) (0)
- Genetic variants of interleukin 1 beta are associated with viral hepatitis-related HCC in Caucasian patients (2021) (0)
- From the Editor's desk...: November 2017. (2017) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- O131 GENOME-WIDE ASSOCIATION STUDY IN AUTOIMMUNE HEPATITIS IDENTIFIES RISK VARIANT IN THE SH2B3 REGION (2014) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- [Therapeutic challenges in viral hepatitis patients]. (2005) (0)
- CT-gestütze Brachytherapie (Afterloading) als therapeutische Option inoperabler hepatozellulärer Karzinome (HCC) (2004) (0)
- Final Results of a roll-over study (107) with Telaprevir, Peginterferon Alfa-2A and Ribavirin in Prior Null Response, Partial Response, Viral Breakthrough or Relapse HCV Genotype 1 Patients After PR (2011) (0)
- From the Editor's Desk…: November 2019. (2019) (0)
- From the Editor's desk...: June 2017. (2017) (0)
- FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial (2019) (0)
- Duodenal microbiota is not the predominent origin for bacterial translocation in liver cirrhosis (2015) (0)
- 426 LONG-TERM OUTCOME (30 YEARS FOLLOW-UP) IN A SINGLE-SOURCE OUTBREAK OF HEPATITIS C GENOTYPE 1B INFECTION IN GERMANY (2009) (0)
- Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial (2020) (0)
- [Liver support methods]. (2013) (0)
- From the Editor's desk....: September 2018. (2018) (0)
- Low ascites levels of cell membrane-derived microparticles indicate worse short-term prognosis in patients with decompensated cirrhosis (2016) (0)
- Dynamic of development of lamivudine-resistant mutants of HBV (YMDD mutations) (2003) (0)
- The composition of the hepatitis B surface antigen (HBsAg) in acute hepatitis B virus (HBV) infections is reproducible in an in vitro model (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas Berg?
Thomas Berg is affiliated with the following schools:
